Literature DB >> 10619496

Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

H J Bernsen1, P F Rijken, J P Peters, J H Bakker, R H Boerman, P Wesseling, A J van der Kogel.   

Abstract

In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined. Vascular parameters and oxygenation status of the xenografts were determined immunohistochemically in frozen sections of the tumors, using the hypoxia marker pimonidazole-hydrochloride to detect hypoxic areas. Tumor vessels in these sections were stained by an endothelial cell marker and perfusion of vessels was visualized by administration of the perfusion marker Hoechst 333342 before harvesting the tumors. The vascular parameters were quantified with an image analysis system. The results show that tumor growth was reduced considerably after suramin treatment. This growth suppression was accompanied by marked changes in vascular architecture. Although the total vascular area and perfused fraction of tumor vessels remained unchanged after suramin treatment, vascular density increased, indicating that more but smaller vessel structures had developed during therapy. These vessel structures were also more homogeneously spread over the tumor area. Control tumors showed extensive areas of hypoxia while in treated tumors hypoxic areas had mostly disappeared. This effect was probably due to the higher density of homogeneously distributed perfused vessel structures in the treated tumors, contributing to an increased oxygenation of the tumor. These observations suggest that suramin therapy can result in marked changes not only in tumor vascularity but also in tumor oxygenation status which may have important consequences for sensitivity of these tumors to other therapies such as radiation treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619496     DOI: 10.1023/a:1006363215260

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Suramin analogues with a 2-phenylbenzimidazole moiety as partial structure; potential anti HIV- and angiostatic drugs, 2: Sulfanilic acid-, benzenedisulfonic acid-, and naphthalenetrisulfonic acid analogues.

Authors:  A Kreimeyer; G Müller; M Kassack; P Nickel; A R Gagliardi
Journal:  Arch Pharm (Weinheim)       Date:  1998-03       Impact factor: 3.751

Review 2.  Suramin: an anticancer drug with unique biological effects.

Authors:  A K Larsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice.

Authors:  H J Bernsen; P F Rijken; H Peters; H Bakker; A J van der Kogel
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

4.  Suramin inhibits C6 glioma-induced angiogenesis in vitro.

Authors:  B L Coomber
Journal:  J Cell Biochem       Date:  1995-06       Impact factor: 4.429

5.  Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; Y Saitoh; S Izumoto; K Mori; T Hayakawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.

Authors:  J Waltenberger; U Mayr; H Frank; V Hombach
Journal:  J Mol Cell Cardiol       Date:  1996-07       Impact factor: 5.000

Review 8.  Angiogenesis in malignant gliomas.

Authors:  K H Plate; W Risau
Journal:  Glia       Date:  1995-11       Impact factor: 7.452

Review 9.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

10.  A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.

Authors:  P S Braddock; D E Hu; T P Fan; I J Stratford; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more
  9 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 3.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 4.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

5.  Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis.

Authors:  Kathleen M Schmainda; Scott D Rand; Allen M Joseph; Rebecca Lund; B Doug Ward; Arvind P Pathak; John L Ulmer; Michael A Badruddoja; Michael A Baddrudoja; Hendrikus G J Krouwer
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

Review 6.  Antiangiogenic therapy in brain tumor models.

Authors:  H J Bernsen; A J van der Kogel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

7.  Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.

Authors:  John J Laterra; Stuart A Grossman; Kathryn A Carson; Glenn J Lesser; Fred H Hochberg; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

8.  A combination treatment with DNA methyltransferase inhibitors and suramin decreases invasiveness of breast cancer cells.

Authors:  Sahra Borges; Heike R Döppler; Peter Storz
Journal:  Breast Cancer Res Treat       Date:  2014-02-08       Impact factor: 4.872

9.  Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.

Authors:  Ken Liu; Xiang Zhang; Weiqi Xu; Jinbiao Chen; Jun Yu; Jennifer R Gamble; Geoffrey W McCaughan
Journal:  Clin Transl Gastroenterol       Date:  2017-06-15       Impact factor: 4.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.